Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.19
ARIA's Cash to Debt is ranked higher than
62% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. ARIA: 2.19 )
ARIA' s 10-Year Cash to Debt Range
Min: 1.04   Max: 24.17
Current: 2.19

1.04
24.17
Equity to Asset 0.50
ARIA's Equity to Asset is ranked higher than
60% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ARIA: 0.50 )
ARIA' s 10-Year Equity to Asset Range
Min: -1.37   Max: 0.84
Current: 0.5

-1.37
0.84
F-Score: 2
Z-Score: -1.42
M-Score: 70.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -600.44
ARIA's Operating margin (%) is ranked higher than
56% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. ARIA: -600.44 )
ARIA' s 10-Year Operating margin (%) Range
Min: -526300   Max: 58.61
Current: -600.44

-526300
58.61
Net-margin (%) -601.74
ARIA's Net-margin (%) is ranked higher than
56% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. ARIA: -601.74 )
ARIA' s 10-Year Net-margin (%) Range
Min: -493975   Max: 194.03
Current: -601.74

-493975
194.03
ROE (%) -147.78
ARIA's ROE (%) is ranked higher than
52% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. ARIA: -147.78 )
ARIA' s 10-Year ROE (%) Range
Min: -204.64   Max: 133.04
Current: -147.78

-204.64
133.04
ROA (%) -73.92
ARIA's ROA (%) is ranked higher than
55% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. ARIA: -73.92 )
ARIA' s 10-Year ROA (%) Range
Min: -123.07   Max: 71.02
Current: -73.92

-123.07
71.02
ROC (Joel Greenblatt) (%) -251.49
ARIA's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. ARIA: -251.49 )
ARIA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2753.99   Max: 1490.69
Current: -251.49

-2753.99
1490.69
Revenue Growth (%) -45.70
ARIA's Revenue Growth (%) is ranked higher than
58% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. ARIA: -45.70 )
ARIA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 214.8
Current: -45.7

0
214.8
» ARIA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ARIA Guru Trades in Q1 2013

Jim Simons 30,681 sh (New)
Louis Moore Bacon 275,000 sh (New)
Daniel Loeb 2,750,000 sh (+10%)
RS Investment Management Sold Out
Columbia Wanger 4,174,000 sh (-13.15%)
Steven Cohen 354,937 sh (-82.27%)
» More
Q2 2013

ARIA Guru Trades in Q2 2013

Columbia Wanger 4,174,000 sh (unchged)
Daniel Loeb Sold Out
Stanley Druckenmiller Sold Out
Jim Simons Sold Out
Louis Moore Bacon 75,000 sh (-72.73%)
Steven Cohen 71,450 sh (-79.87%)
» More
Q3 2013

ARIA Guru Trades in Q3 2013

Manning & Napier Advisors, Inc 504,530 sh (New)
Columbia Wanger 5,291,000 sh (+26.76%)
Steven Cohen 56,180 sh (-21.37%)
Louis Moore Bacon 50,000 sh (-33.33%)
» More
Q4 2013

ARIA Guru Trades in Q4 2013

Paul Tudor Jones 18,432 sh (New)
Chuck Royce 686,602 sh (New)
George Soros 1,950,000 sh (New)
Steven Cohen 93,800 sh (+66.96%)
Columbia Wanger Sold Out
Louis Moore Bacon Sold Out
Manning & Napier Advisors, Inc Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARIA

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2013-12-31 New Buy0.11%$2.2 - $18.8 $ 7.138%1950000
Daniel Loeb 2013-06-30 Sold Out 0.94%$16.32 - $19.77 $ 7.1-60%0
Daniel Loeb 2012-12-31 Add 85.19%0.4%$18.93 - $25.16 $ 7.1-68%2500000
Daniel Loeb 2012-09-30 Reduce -35.71%0.39%$17.11 - $24.21 $ 7.1-64%1350000
Daniel Loeb 2012-06-30 New Buy1.1%$14.6 - $17.82 $ 7.1-57%2100000
George Soros 2012-06-30 Sold Out 0.15%$14.6 - $17.82 $ 7.1-57%0
George Soros 2012-03-31 New Buy0.15%$12.73 - $16.32 $ 7.1-48%635000
George Soros 2011-12-31 Sold Out 0.07%$8.03 - $12.5 $ 7.1-35%0
George Soros 2011-09-30 New Buy0.07%$7.63 - $13.34 $ 7.1-33%496847
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.30
ARIA's P/B is ranked lower than
53% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ARIA: 7.30 )
ARIA' s 10-Year P/B Range
Min: 1.69   Max: 125.8
Current: 7.3

1.69
125.8
P/S 28.80
ARIA's P/S is ranked lower than
69% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. ARIA: 28.80 )
ARIA' s 10-Year P/S Range
Min: 1.71   Max: 705
Current: 28.8

1.71
705
EV-to-EBIT 3.70
ARIA's EV-to-EBIT is ranked higher than
89% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. ARIA: 3.70 )
ARIA' s 10-Year EV-to-EBIT Range
Min: 2.4   Max: 13.4
Current: 3.7

2.4
13.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 25.40
ARIA's Price/Net Cash is ranked lower than
72% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. ARIA: 25.40 )
ARIA' s 10-Year Price/Net Cash Range
Min: 4.06   Max: 168.8
Current: 25.4

4.06
168.8
Price/Net Current Asset Value 24.50
ARIA's Price/Net Current Asset Value is ranked lower than
71% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. ARIA: 24.50 )
ARIA' s 10-Year Price/Net Current Asset Value Range
Min: 3.96   Max: 33.07
Current: 24.5

3.96
33.07
Price/Tangible Book 7.20
ARIA's Price/Tangible Book is ranked lower than
51% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ARIA: 7.20 )
ARIA' s 10-Year Price/Tangible Book Range
Min: 0.94   Max: 28.63
Current: 7.2

0.94
28.63
Price/Median PS Value 0.30
ARIA's Price/Median PS Value is ranked higher than
95% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ARIA: 0.30 )
ARIA' s 10-Year Price/Median PS Value Range
Min: 0.03   Max: 5.33
Current: 0.3

0.03
5.33
Earnings Yield (Greenblatt) 27.10
ARIA's Earnings Yield (Greenblatt) is ranked higher than
85% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ARIA: 27.10 )
ARIA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 7.5   Max: 40.9
Current: 27.1

7.5
40.9
Forward Rate of Return (Yacktman) -6.35
ARIA's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. ARIA: -6.35 )
ARIA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -21.7   Max: -4.2
Current: -6.35

-21.7
-4.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:APS.Germany
Ariad Pharmaceuticals was organized as a Delaware corporation in April 1991. It develops targeted therapies to treat solid tumors and hematologic cancers, as well as the spread of primary tumors to distant sites. are building a pipeline of product candidates that has the potential to expand and improve upon current treatment options for patients with cancer. Each of its product candidates -- ponatinib, AP26113 and ridaforolimus- was discovered internally by scientists based on expertise in cell-signaling, cancer biology and structure-based drug design. Ponatinib is an investigational, pan BCR-ABL inhibitor that it believe has potential applications in various hematological cancers and solid tumors. It has completed enrollment in pivotal Phase 2 clinical trial in patients with resistant or intolerant chronic myeloid leukemia, or CML, and Philadelphia positive acute lymphoblastic leukemia, or Ph+ ALL; AP26113 is an investigational dual inhibitor of anaplastic lymphoma kinase, or ALK, and Ridaforolimus is an investigational mTOR inhibitor that it discovered internally and later licensed in 2010 to Merck, Sharpe & Dohme Corp., or Merck. epidermal growth factor receptor, or EGFR; and The company's drug discovery program builds on its expertise in cell signaling, cancer biology, structure-based drug design and computational chemistry in designing and characterizing small-molecule drugs, such as deforolimus and AP24534, to treat disease. The company pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., Celgene Corporation and Pfizer, Inc., are developing and marketing drugs to treat cancer.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide